Abstract

- Early Phase Clinical Research Support (EPCRS) The Early Phase Clinical Research Support (EPCRS) provides critical resources for innovative short duration research protocols at UNC Lineberger Comprehensive Cancer Center (LCCC) in the form of skilled and specialized research coordinator, data management, and laboratory support. The trials supported by this resource are: complex with strong correlative science and/or pharmacokinetic and pharmacodynamic components; LCCC investigator-initiated; and primarily based on scientific expertise and interests of LCCC members. Trials are selected from among those submitted to the Protocol Office Executive Committee for review. Dr Claire Dees, EPCRS Faculty Director and co-leader, Clinical Research Program, in direct consultation with Drs. Carey (Associate Director, Clinical Sciences) and Hayes (co-leader, Clinical Research Program), makes the final selection. LCCC members conducted numerous innovative studies over the last five years including those: evaluating novel compounds with radiation; involving novel combinations; and incorporating novel correlative biomarkers and imaging. Many ECPRS supported trials originated in basic and preclinical science in UNC Lineberger laboratories. Since 2010, LCCC recruited a number of talented investigators actively growing our Phase I investigator initiated trial portfolio and so we anticipate expanded ECPRS use. In addition, the inaugural trials of the UNC immunotherapy center will begin in this cycle and will require additional specialized support. The first patients will be enrolled on UNC immunotherapy trials in the spring of 2016 and these initial trials would include patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and multiple myeloma. The strong commitment of the UNC Lineberger leadership to the development of novel therapeutics as a Cancer Center strategic direction creates an environment that will generate even greater demand for specialized support.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-41
Application #
9316474
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost

  Institution

Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599

  Publications

Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024
Buist, Diana S M; Abraham, Linn; Lee, Christoph I et al. (2018) Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Intern Med 178:458-468

Showing the most recent 10 out of 1525 publications